


Revolutionary GLP-1 Tracking App Solves Ozempic & Wegovy Users' Biggest Problem After 3,000-Person Beta Test

Revolutionary iOS App Now Publicly Available After Successful Testing Phase, Offering Complete Solution for Ozempic, Wegovy, Mounjaro, and Zepbound Users

SAN FRANCISCO, CA, UNITED STATES, August 12, 2025 /EINPresswire.com/ -- Jabby, an innovative [GLP-1 injection tracking app](#), today announced its official public launch following the successful completion of its beta testing phase with over 3,000 users. The comprehensive iOS application is now available to all patients managing their weight loss and diabetes treatment with GLP-1 medications.


After extensive testing and refinement based on user feedback, Jabby's comprehensive GLP1 tracking platform addresses the critical need for medication adherence among users of popular GLP-1 receptor agonists including Ozempic, Wegovy, Mounjaro, and Zepbound. The beta testing phase validated the app's effectiveness in helping patients optimize their treatment outcomes.

"Following our successful beta phase with 3,000 dedicated testers, we're excited to bring Jabby to the broader community of GLP-1 medication users," said Kathrine the head of product development at Jabby. "The feedback from our beta users has been instrumental in refining the app's features and ensuring it truly meets the needs of patients managing their treatment journey."



The public launch version includes key features developed and tested during the beta phase: custom injection reminders that adapt to individual medication schedules, seamless integration with popular health apps like MyFitnessPal and Apple Health, advanced analytics for tracking weight loss progress and side effects, unlimited dose history storage with secure iCloud backup, and comprehensive reporting capabilities designed for healthcare provider consultations.

Beta testers particularly praised the app's sophisticated side effect monitoring system, which allows users to track common GLP-1 medication symptoms including nausea, injection site reactions, and appetite changes. Healthcare professionals who evaluated [Jabby for medication adherence monitoring](#) during the testing phase noted its robust data export capabilities and clinical-grade tracking features.



Now available free on the App Store, Jabby launches with enterprise-grade privacy standards and HIPAA compliance guidelines established during development. The platform's secure iCloud integration ensures patient data remains protected while enabling seamless synchronization across all Apple devices.

For more information about Jabby and to download the app, visit <https://getjabby.com/>

About Jabby:

Jabby is a newly launched iOS application for GLP-1 injection tracking, developed following extensive beta testing with over 3,000 users. The app provides comprehensive tools for patients managing their weight loss and diabetes journey with medications like Ozempic, Wegovy, Mounjaro, and Zepbound, offering dose tracking, progress monitoring, and healthcare provider communication features.

###

Jabby is a medication tracking tool and is not a substitute for professional medical advice. Users should consult healthcare providers for medical guidance.

PR Team

Tamerza LCC
[email us here](#)

Visit us on social media:

[TikTok](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/838012863>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.